Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262591 | 0.85 | KMT2A (0.55) | KMT2ANPSR1MEN1GAACA12 | |
| SCHEMBL7088667 | 0.83 | CA12 (0.49) | KMT2ANPSR1MEN1GAACA12 | |
| SCHEMBL24658682 | 0.82 | KMT2A (0.52) | KMT2ANPSR1MEN1GAACA12 | |
| SCHEMBL30901404 | 0.82 | KMT2A (0.52) | KMT2ANPSR1MEN1GAACA12 | |
| SCHEMBL7828967 | 0.82 | POLB (0.44) | KMT2ANPSR1MEN1GAACA12 | |
| SCHEMBL9004471 | 0.81 | POLB (0.50) | KMT2ANPSR1MEN1GAACA12 | |
| SCHEMBL5664657 | 0.81 | POLB (0.50) | KMT2ANPSR1MEN1GAACA12 | |
| SCHEMBL5754683 | 0.81 | KMT2A (0.43) | KMT2ANPSR1MEN1GAACA12 | |
| SCHEMBL7160912 | 0.81 | POLB (0.68) | KMT2ANPSR1MEN1LMNAPOLB | |
| SCHEMBL3586790 | 0.81 | KMT2A (0.51) | KMT2ANPSR1MEN1GAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1408985-A4 | NOVEL PYRIDOPYRIMIDONES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1408985-A1 | NOVEL PYRIDOPYRIMIDONES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030100572-A1 | Novel pyridopyrimidones and uses thereof | ARIAD PHARMACEUTICALS,INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000270-A1 | NOVEL PYRIDOPYRIMIDONES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1246829-A1 | NOVEL HETEROCYCLES | ARIAD PHARMACEUTICALS, INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020103161-A1 | Novel heterocycles | ARIAD PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001044258-A1 | NOVEL HETEROCYCLES | ARIAD PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100572-A1 | Novel pyridopyrimidones and uses thereof | UQCRB, RRM2B, CYP2B6 | KMT2A 3838/4885NPSR1 1093/4885MEN1 1770/4885 |
| US-20020103161-A1 | Novel heterocycles | BMP2, SOST, BMP4 | KMT2A 3040/4885NPSR1 906/4885MEN1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.